VIVX.F Stock Overview
Focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Avivagen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.0036 |
52 Week High | CA$0.012 |
52 Week Low | CA$0.0004 |
Beta | 1 |
11 Month Change | 200.00% |
3 Month Change | n/a |
1 Year Change | -68.70% |
33 Year Change | -98.97% |
5 Year Change | -99.35% |
Change since IPO | -99.44% |
Recent News & Updates
Recent updates
Shareholder Returns
VIVX.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0% | -0.3% | 0.07% |
1Y | -68.7% | 17.1% | 20.7% |
Return vs Industry: VIVX.F underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: VIVX.F underperformed the US Market which returned 20.7% over the past year.
Price Volatility
VIVX.F volatility | |
---|---|
VIVX.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VIVX.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VIVX.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | n/a | G. F. Anthony | www.avivagen.com |
Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand.
Avivagen Inc. Fundamentals Summary
VIVX.F fundamental statistics | |
---|---|
Market cap | US$283.93k |
Earnings (TTM) | -US$4.64m |
Revenue (TTM) | US$715.22k |
0.0x
P/S Ratio0.0x
P/E RatioIs VIVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIVX.F income statement (TTM) | |
---|---|
Revenue | CA$715.22k |
Cost of Revenue | CA$409.83k |
Gross Profit | CA$305.39k |
Other Expenses | CA$4.95m |
Earnings | -CA$4.64m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.06 |
Gross Margin | 42.70% |
Net Profit Margin | -648.74% |
Debt/Equity Ratio | -78.1% |
How did VIVX.F perform over the long term?
See historical performance and comparison